Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novaccess Global Inc
(OP:
XSNX
)
0.0071
UNCHANGED
Last Price
Updated: 9:41 AM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novaccess Global Inc
< Previous
1
2
Next >
NovAccess Global Files Patent with Cedars-Sinai to Advance its Brain Cancer Fighting Vaccine Platform
May 21, 2024
Via
ACCESSWIRE
NovAccess Global Advisory on Annual Meeting of Shareholders
May 07, 2024
Via
ACCESSWIRE
NovAccess Global Announces New License to Advance its Immunotherapy Platform
April 30, 2024
Via
ACCESSWIRE
NovAccess Global Announces $10.7 Million Financing
January 02, 2024
Via
ACCESSWIRE
NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board
November 10, 2023
Via
ACCESSWIRE
NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy Platform
July 27, 2023
Via
ACCESSWIRE
NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine Advancements
May 11, 2023
Via
ACCESSWIRE
Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award
March 15, 2023
Via
ACCESSWIRE
NovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness Day
July 13, 2023
Via
ACCESSWIRE
NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine Division
June 16, 2023
Via
ACCESSWIRE
NovAccess Global Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalized Healthcare Therapies
June 01, 2023
Via
ACCESSWIRE
NovAccess Global to Present at World Orphan Drug Congress
February 16, 2023
Via
ACCESSWIRE
NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress
February 03, 2023
Via
ACCESSWIRE
NovAccess Global Announces Fireside Chat with Dr. Christopher Wheeler, the Company’s Lead Scientist and President of its StemVax Therapeutics Division
January 05, 2023
Via
ACCESSWIRE
NovAccess Global Announces Initial Fireside Chat with Glioblastoma Patient Advocate
November 22, 2022
Via
ACCESSWIRE
NovAccess Global Announces Virtual Annual Shareholders' Meeting
November 08, 2022
Via
ACCESSWIRE
NovAccess Global Appoints Healthcare IP Consultant Dr. Peter Weinstein to Scientific Advisory Board
November 10, 2022
Via
ACCESSWIRE
NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1
October 26, 2022
Via
ACCESSWIRE
NovAccess Global Announces Fireside Chat with Board Member Perspectives
October 20, 2022
Via
ACCESSWIRE
NovAccess Global Announces Fireside Chat Series for the Investment Community
September 29, 2022
Via
ACCESSWIRE
NovAccess Global Announces Effectiveness of Form S-1 Registration Statement
September 22, 2022
Via
ACCESSWIRE
NovAccess Global Announces Uplisting to OTCQB
August 10, 2022
Via
ACCESSWIRE
CORRECTION: NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
July 19, 2022
Via
ACCESSWIRE
NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
July 19, 2022
Via
ACCESSWIRE
CORRECTION: NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
July 19, 2022
This corrects the release that ran earlier today, replacing the name of the executive quoted in the press release and other minor edits.
From
NovAccess Global Inc.
Via
AccessWire
Exposures
Product Safety
NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
July 19, 2022
Accelerating on the Path Toward Immunotherapy for Glioblastoma (Brain Cancer)
From
NovAccess Global Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
NovAccess Global CEO Dwain Irvin Featured on MoneyTV
June 14, 2022
CLEVELAND, OH / ACCESSWIRE / June 14, 2022 / NovAccess Global Inc. (OTC PINK:XSNX) announced that its Chief Executive Officer Dr. Dwain Irvin was a featured guest on MoneyTV, an...
From
NovAccess Global Inc.
Via
AccessWire
Exposures
Product Safety
This Week on MoneyTV with Donald Baillargeon, 6/10
June 10, 2022
HOLLYWOOD, CA / ACCESSWIRE / June 10, 2022 / Cancer treatment, metaverse, coping; this week on MoneyTV with Donald Baillargeon
From
MoneyTV
Via
AccessWire
NovAccess Global to Participate in LD Micro Invitational XII Conference
May 19, 2022
CLEVELAND, OH / ACCESSWIRE / May 19, 2022 / NovAccess Global Inc. (OTC PINK:XSNX) announced that its Chief Executive Officer Dr. Dwain Irvin is scheduled to participate in the LD Micro Invitational XII...
From
NovAccess Global Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
NovAccess Global Stock Redemption and Expanded Board of Directors Reinforces Shareholder Value and Positions the Company to Accelerate Objectives
March 17, 2022
LOS ANGELES, CA / ACCESSWIRE / March 17, 2022 / NovAccess Global Inc. (OTC PINK:XSNX) announced today the closing of a series of transactions which results in the reduction of potential common stock...
From
NovAccess Global Inc.
Via
AccessWire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.